Sionna Therapeutics is cutting nearly half its workforce at its Waltham headquarters, a month after its experimental cystic fibrosis drug flopped in a clinical trial and wiped out roughly $2 billion in stock value in a single day. The biotech's board approved the restructuring plan on September 9, and the cuts eliminate approximately 27 of the company's 59 jobs.
The layoffs come one month after the company disclosed that its lead drug, SION-719, failed to show a meaningful benefit when added to Trikafta, the standard-of-care cystic fibrosis treatment made by rival Vertex Pharmaceuticals, according to NBC Boston. The Phase 2a PreciSION CF trial tested SION-719 in just 15 adult patients and produced a placebo-adjusted sweat chloride reduction of only -1.0 mmol/L, a result so weak it carried a p-value of 0.7, as reported by BioPharma Dive. Sweat chloride levels are the primary biomarker scientists use to judge whether a CFTR-targeting drug is actually restoring protein function.
[b2] The market reaction was brutal. Following the August 10 trial failure announcement, Sionna's stock cratered 91.2%, plunging $46.54 to close at just $4.10 a share, according to reporting from Endpoints News and WBOC. That single-day collapse erased close to $2 billion in market capitalization for a company that had gone public in February 2025.
How the Company Scaled Up, Then Scaled Back
Sionna's rise and retreat trace back to a February 2025 initial public offering, when the company raised $191 million by selling nearly 10.6 million shares at $18 apiece on the Nasdaq, per BioPharma Dive. The IPO cash fueled a hiring push as Sionna positioned SION-719 as a direct challenge to Vertex, which dominates the global cystic fibrosis market, treating roughly 90% of diagnosed patients and pulling in more than $10 billion a year from its CF franchise, the outlet reported.
[b5] An SEC Form 8-K filing summarized by Stock Titan shows the restructuring will cost Sionna about $6.4 million in total charges. That includes $5.3 million for employee severance and post-employment benefits, plus another $0.7 million to close out clinical contracts tied to the discontinued program. The same filing notes that Chief Business Officer Caroline Stark Beer, who joined the company in September 2025, is scheduled to depart effective September 15, 2026. The board also approved an employee stock option repricing plan taking effect September 17, tied to an 18-month retention requirement meant to keep remaining staff in place.
A Second Shot at Cystic Fibrosis
Sionna, led by CEO Mike Cloonan, isn't walking away from cystic fibrosis entirely. A post-hoc analysis of the SION-719 trial data, after excluding three non-adherent patients, showed a mean sweat chloride reduction of -8.6 mmol/L, according to Fierce Biotech. That finding is pushing the company toward a new Phase 2a trial called AscenSION CF, testing a dual combination of SION-451 and SION-2222 in patients who switch off Trikafta entirely, expected to begin in the first quarter of 2027.
The strategic shift means Sionna is betting on an all-proprietary combination therapy rather than trying to supplement Vertex's existing drug. As of February 2026, the company employed 59 people total, according to its annual report as cited by Endpoints News, meaning the 46% reduction removes roughly 27 positions from the Waltham operation.
Cash Runway Stretches Toward 2029
Despite the trial failure and stock wipeout, Sionna says it isn't running out of money. The company held $268.3 million in cash, cash equivalents, and marketable securities as of June 30, and management expects that balance, combined with the restructuring savings, to extend its operating runway into the second half of 2029, according to a company release cited by BioSpace.
The Waltham cuts also land amid a broader pullback across the state's life sciences sector. A MassBio industry snapshot released in August found that Massachusetts biopharma employment fell 3.1% in 2025, driven by a 3.9% drop in research and development roles that eliminated 2,563 R&D jobs statewide, per BioSpace. Sionna's reduction adds a fresh, concrete example to a regional trend that has followed two decades of steady growth in the state's biopharma cluster.
